Remove 2018 Remove Access Remove Clinical Trials Remove Data
article thumbnail

With $20M to spend on marijuana research for veteran care, Michigan seeks proposals

Cannabis Law Report

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. Veteran suicides made up about 14% of total suicides in America in 2018, according to the U.S. Department of Veteran Affairs’ most recent data.

article thumbnail

UK: David Hardstaff And John Binns Write For Open Access Government Exploring Shifting Sands In The UK CBD Industry

Cannabis Law Report

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Explore the Latest Studies for Veteran PTSD Research

Veriheal

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? McNabb and team also mentioned a study conducted in 2018 by Shishko and colleagues. Let’s find out. .

Treatment 104
article thumbnail

Pain Relief: Marijuana vs. Opioids

CannaMD

In the fall of 2018, scientists at the San Francisco Veterans Affairs Medical Center released findings from a survey on the subject of marijuana versus opioids. As more people gain access to medical marijuana, dependence on opioids for pain relief is likely to decline. billion opioid prescriptions written between 2011 and 2018.

article thumbnail

Dales Report: 10 Psychedelic Companies To Watch In 2022

Cannabis Law Report

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

article thumbnail

Medical cannabis studies offer hope to opioid users

Healer

The results were published in the Cureus Journal of Medical Science, an open-access general medical journal known for its use of crowdsourcing in its peer-review process. . The researchers stressed the need for large, well-designed clinical trials. percent at the start to 23.9 percent after 12 months. .

article thumbnail

22q11.2 Deletion Syndrome – Global Market Insights, Epidemiology and Forecast to 2030 – ResearchAndMarkets.com

Cannabis Law Report

deletion syndrome in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030. Zynerba Pharmaceuticals is currently developing the Zygel in Phase II (ACTRN12619000673145; INSPIRE) of the clinical development in Children and Adolescents with 22q11.2 Deletion Syndrome.